{
    "clinical_study": {
        "@rank": "131331", 
        "brief_summary": {
            "textblock": "To determine the safety and tolerance of subcutaneous injections of natural interferon alpha\n      (IFN) in asymptomatic HIV-positive persons and record its effects on the HIV virus in these\n      individuals."
        }, 
        "brief_title": "Phase I Study of Alferon N Injection in Persons With Asymptomatic Human Immunodeficiency Virus (HIV) Infection", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "Acquired Immunodeficiency Syndrome", 
                "HIV Infections", 
                "Immunologic Deficiency Syndromes"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patients must have:\n\n          -  HIV-1 seropositivity.\n\n          -  CD4 count > 400/mm3.\n\n          -  Eligibility for care in the military medical system.\n\n        Prior Medication:\n\n        Allowed:\n\n          -  Acyclovir.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following symptoms or conditions are excluded:\n\n          -  AIDS- or ARC-defining condition (unexplained weight loss, fever, diarrhea, night\n             sweats).\n\n          -  Evidence of AIDS dementia.\n\n          -  Chronic hepatitis with severe liver dysfunction.\n\n          -  Active gastrointestinal, renal, respiratory, endocrine, hematologic, cardiovascular,\n             or psychiatric disorder that would limit ability to complete the study.\n\n          -  Hemophilia.\n\n          -  Co-existent disease likely to result in death within the next 2 years.\n\n          -  Known hypersensitivity to human interferon alpha.\n\n          -  Known anaphylactic hypersensitivity to mouse immunoglobulin (IgG), egg protein, or\n             neomycin.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Any other concurrent experimental medications.\n\n        Patients with the following prior conditions are excluded:\n\n          -  History of AIDS- or ARC-defining condition (unexplained weight loss, fever, diarrhea,\n             night sweats).\n\n          -  Evidence of chronic hepatitis with severe liver dysfunction.\n\n        Prior Medication:\n\n        Excluded within 5 days prior to study entry:\n\n          -  Immunosuppressive agents.\n\n          -  Chemotherapy.\n\n          -  Steroids.\n\n        Excluded within 45 days prior to study entry:\n\n          -  BCG vaccine.\n\n          -  Isoprinosine.\n\n          -  Other immune modulators.\n\n        Excluded within 3 months prior to study entry:\n\n          -  Any form of interferon.\n\n          -  Antiviral therapy.\n\n          -  Immunoregulatory therapy (other than acyclovir).\n\n             1. Active drug abuse (narcotic or alcohol abuse documented within the past 6 months).\n\n          -  Unlikely or unable to comply with the requirements of the protocol."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002078", 
            "org_study_id": "082A"
        }, 
        "intervention": {
            "intervention_name": "Interferon alfa-n3", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Interferon-alpha", 
                "Interferon Alfa-2a", 
                "Interferons"
            ]
        }, 
        "keyword": [
            "Drug Evaluation", 
            "Interferon-alpha"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Washington", 
                        "country": "United States", 
                        "state": "District of Columbia", 
                        "zip": "20307"
                    }, 
                    "name": "Walter Reed Army Institute of Research"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bethesda", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "20889"
                    }, 
                    "name": "Natl Naval Med Ctr"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Phase I Study of Alferon N Injection in Persons With Asymptomatic Human Immunodeficiency Virus (HIV) Infection", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "reference": {
            "citation": "Skillman DR, Wagner K, Malone JL, Decker C, Paparello S, Meltzer MS. Phase 1 study of interferon alfa-N3 in asymptomatic HIV-infected persons. Int Conf AIDS. 1993 Jun 6-11;9(1):468 (abstract no PO-B26-1998)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002078"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Walter Reed Army Institute of Research (WRAIR)", 
                    "agency_class": "U.S. Fed"
                }, 
                {
                    "agency": "Henry M Jackson Foundation", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Purdue Frederick", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 1993"
    }, 
    "geocoordinates": {
        "Natl Naval Med Ctr": "38.985 -77.095", 
        "Walter Reed Army Institute of Research": "38.895 -77.036"
    }
}